Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulised heparin for COVID-19 lung injury
NCT04511923Phase 2Completed
- Sponsor
- University Hospital Galway
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of heparin in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), acute lung injury (ALI), sponsored by University Hospital Galway. Started Dec 2020; status: completed.
02
Drugs
heparin
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)acute lung injury (ALI)
Beyond the preview
Go deeper on NCT04511923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04511923.